Controlled study for Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
Phase 3
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-jRCT2080220356
- Lead Sponsor
- ovartis Pharma K.K., ONO Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion criteria
1.A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria
2.A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria
3.An MMSE score of >= 10 and = 20
Exclusion criteria
1.A current DSM-IV diagnosis of major depression
2.Taken rivastigmine in the past
3.A score of > 5 on the Modified Hachinski Ischemic Scale (MHIS)
Other protocol-defined inclusion/exclusion criteria may apply
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety /Efficacy
- Secondary Outcome Measures
Name Time Method